On International Women’s Day, pharmaphorum looks back to an interview with Miruna Sasu, PhD, CEO of COTA, a real-world data company that is advancing generative AI models for cancer care.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.